Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05898074 · ClinicalTrials.gov registry record · NA

Role of Novel RADA16 Hydrogel in Endoscopic Skull Base Surgery

A NA study of Skull Base Neoplasms and Cerebrospinal Fluid Leakage, sponsored by Indiana University.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT05898074 is a NA study of Skull Base Neoplasms and Cerebrospinal Fluid Leakage that is actively recruiting participants, run by Indiana University. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05898074, a NA study of Skull Base Neoplasms and Cerebrospinal Fluid Leakage, is actively recruiting participants, sponsored by Indiana University.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to specifically evaluate the effectiveness of PuraGel, a RADA16 polypeptide hydrogel, in expediting post-operative healing and re-mucosalization of the nasoseptal flap harvest site during endoscopic skull base surgery and the impact on patient and sinonasal morbidity.

Interventions

  • DEVICE Non-Absorbable Packing (Silastic Splint)
  • DEVICE PuraGel (RADA16) Hydrogel

Study Locations (1)

Indiana

  • Indiana University - Indianapolis

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2023-10-09
Est. Completion 2025-10-09
Phase NA

Sponsor

Indiana University

890 total trials

What the Registry Record Tells You About NCT05898074

The ClinicalTrials.gov registry entry for NCT05898074 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Skull Base Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Non-Absorbable Packing (Silastic Splint) is the first listed.

NCT05898074 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.

Frequently Asked Questions

What is clinical trial NCT05898074 about?

NCT05898074 is a clinical study titled "Role of Novel RADA16 Hydrogel in Endoscopic Skull Base Surgery". The purpose of this study is to specifically evaluate the effectiveness of PuraGel, a RADA16 polypeptide hydrogel, in expediting post-operative healing and re-mucosalization of the nasoseptal flap harvest site during endoscopic skull base surgery and the impact on patient and sinonasal morbidity.

What is the current status of trial NCT05898074?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2023-10-09. Estimated completion is 2025-10-09.

What conditions does trial NCT05898074 study?

This clinical trial studies the following conditions: Skull Base Neoplasms, Cerebrospinal Fluid Leakage, Nasal; Hypertrophy, Mucous Membrane (Septum).

What interventions are being tested in trial NCT05898074?

The interventions under investigation include: Non-Absorbable Packing (Silastic Splint) (DEVICE), PuraGel (RADA16) Hydrogel (DEVICE).

Who is sponsoring clinical trial NCT05898074?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05898074 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Skull Base Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.